Taken together, IFNα treatment could serve as a promising alternative therapeutic strategy for DBA patients, and the combination of IFNα and Dex treatment might potentially achieve an even greater clinical efficacy. This evidence concerns the gene IFNA1 and Diamond-Blackfan anemia.